Safety & Efficacy Study of TPI 287 + Avastin in Adults With Glioblastoma That Progressed Following Prior Avastin Therapy
Status:
Terminated
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, maximum tolerated dose (MTD), and
efficacy of TPI 287 in combination with Avastin (bevacizumab) in subjects who have
glioblastoma multiforme (GBM) that has progressed following prior radiation and temozolomide
(TMZ) therapy and that has progressed following prior bevacizumab therapy.